Video Experimental Relacionado
Updated: May 22, 2026
07:35
Gene Transfer for Ischemic Heart Failure in a Preclinical Model
Published on: May 15, 2011
Terapia de la cardiomiopatía isquémica con el agente inmunomodulador pentoxifilina: resultados de un estudio
Karen Sliwa1, Angela Woodiwiss, Veuvette N Kone
1Department of Cardiology, Chris-Hani Baragwanath Hospital, Johannesburg, South Africa.
Circulation
|February 19, 2004
Resumen
La pentoxifilina mejoró la función cardíaca y redujo los marcadores de inflamación en pacientes con cardiomiopatía isquémica. Este tratamiento de la insuficiencia cardíaca mejoró el estado clínico y la fracción de eyección, ofreciendo una nueva vía terapéutica.
Área de la Ciencia:
- Cardiología Cardiología.
- Inmunología Inmunología.
- Farmacología Farmacología.
Sus antecedentes:
- La activación inmune inflamatoria es común en la insuficiencia cardíaca y puede empeorar la condición.
- Investigar los agentes inmunomoduladores puede ofrecer nuevas estrategias terapéuticas para la insuficiencia cardíaca.
- La pentoxifilina es un agente inmunomodulador con beneficios potenciales en enfermedades cardiovasculares.
Objetivo del estudio:
- Para determinar si la pentoxifilina mejora la función ventricular izquierda en pacientes con cardiomiopatía isquémica.
- Para evaluar el efecto de la pentoxifilina en marcadores inflamatorios, marcadores de pronóstico y marcadores de apoptosis.
- Evaluar la pentoxifilina como terapia adyuvante a la atención estándar para la insuficiencia cardíaca.
Principales métodos:
- Un estudio prospectivo, aleatorizado, doble ciego, controlado con placebo.
- 38 pacientes con cardiomiopatía isquémica recibieron pentoxifilina o placebo durante 6 meses.
- Evaluación clínica evaluada, ventriculografía de radionucleidos, ecocardiografía y análisis de sangre.
Principales resultados:
- La pentoxifilina mejoró la clase funcional, la presión arterial sistólica y la fracción de eyección ventricular izquierda.
- Se observaron reducciones significativas en la proteína C reactiva (CRP), el NT-pro BNP, el factor de necrosis tumoral alfa (TNF-alfa) y Fas/Apo-1.
- Se produjeron menos muertes en el grupo de pentoxifilina en comparación con el grupo de placebo.
Conclusiones:
- La pentoxifilina mejora el estado clínico y la función cardíaca en pacientes con insuficiencia cardíaca con disfunción ventricular izquierda isquémica.
- La terapia con pentoxifilina conduce a una disminución de los niveles plasmáticos de inflamación, pronóstico y marcadores de apoptosis.
- La pentoxifilina es una adición prometedora a la terapia estándar para el manejo de la cardiomiopatía isquémica.
Videos de Conceptos Relacionados
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:16Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue, improving...
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue, improving...
01:14Myocarditis III: Medical Management
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
01:30Acute Coronary Syndrome III: Diagnostic Studies
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...